1. Home
  2. YMAB vs DOGZ Comparison

YMAB vs DOGZ Comparison

Compare YMAB & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • DOGZ
  • Stock Information
  • Founded
  • YMAB 2015
  • DOGZ 2003
  • Country
  • YMAB United States
  • DOGZ China
  • Employees
  • YMAB N/A
  • DOGZ N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • DOGZ Miscellaneous manufacturing industries
  • Sector
  • YMAB Health Care
  • DOGZ Consumer Discretionary
  • Exchange
  • YMAB Nasdaq
  • DOGZ Nasdaq
  • Market Cap
  • YMAB 482.4M
  • DOGZ 547.0M
  • IPO Year
  • YMAB 2018
  • DOGZ 2017
  • Fundamental
  • Price
  • YMAB $6.19
  • DOGZ $28.76
  • Analyst Decision
  • YMAB Strong Buy
  • DOGZ
  • Analyst Count
  • YMAB 10
  • DOGZ 0
  • Target Price
  • YMAB $21.10
  • DOGZ N/A
  • AVG Volume (30 Days)
  • YMAB 417.3K
  • DOGZ 334.7K
  • Earning Date
  • YMAB 02-27-2025
  • DOGZ 02-16-2025
  • Dividend Yield
  • YMAB N/A
  • DOGZ N/A
  • EPS Growth
  • YMAB N/A
  • DOGZ N/A
  • EPS
  • YMAB N/A
  • DOGZ N/A
  • Revenue
  • YMAB $84,553,000.00
  • DOGZ $14,847,902.00
  • Revenue This Year
  • YMAB $6.09
  • DOGZ N/A
  • Revenue Next Year
  • YMAB $19.62
  • DOGZ N/A
  • P/E Ratio
  • YMAB N/A
  • DOGZ N/A
  • Revenue Growth
  • YMAB N/A
  • DOGZ N/A
  • 52 Week Low
  • YMAB $6.01
  • DOGZ $2.90
  • 52 Week High
  • YMAB $20.90
  • DOGZ $58.50
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 19.68
  • DOGZ 39.15
  • Support Level
  • YMAB $6.05
  • DOGZ $26.21
  • Resistance Level
  • YMAB $6.81
  • DOGZ $48.30
  • Average True Range (ATR)
  • YMAB 0.49
  • DOGZ 9.25
  • MACD
  • YMAB -0.02
  • DOGZ -1.55
  • Stochastic Oscillator
  • YMAB 6.90
  • DOGZ 48.27

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

Share on Social Networks: